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Abstract
The aim of this study was to evaluate the safety and efficacy of autologous bone
marrow mononuclear cell transplantation combined with educational intervention
for children with autism spectrum disorder. An open-label clinical trial was per-
formed from July 2017 to August 2019 at Vinmec International Hospital, Hanoi,
Vietnam. Thirty children who fulfilled the autism criteria of the Diagnostic and Sta-
tistical Manual of Mental Disorders, Fifth Edition, and had Childhood Autism Rat-
ing Scale (CARS) scores >37 were selected. Bone marrow was harvested by
anterior iliac crest puncture under general anesthesia. The volume collected was as
follows: 8 mL/kg for patients under 10 kg (80 mL + [body weight in kg
− 10] × 7 mL) for patients above 10 kg. Mononuclear cells were isolated with a
Ficoll gradient and then infused intrathecally. The same procedure was repeated
6 months later. After the first transplantation, all patients underwent 8 weeks of
educational intervention based on the Early Start Denver Model. There were no
severe adverse events associated with transplantation. The severity of autism spec-
trum disorder (ASD) was significantly reduced, with the median CARS score
decreasing from 50 (range 40-55.5) to 46.5 (range 33.5-53.5) (P < .05). Adaptive
capacity increased, with the median Vineland Adaptive Behavior Scales score rising
from 53.5 to 60.5. Social communication, language, and daily skills improved mark-
edly within 18 months after transplantation. Conversely, repetitive behaviors and
hyperactivity decreased remarkably. Autologous bone marrow mononuclear cell
transplantation in combination with behavioral intervention was safe and well tol-
erated in children with ASD (Trial registration: ClinicalTrials.gov identifier:
NCT03225651).
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1 | INTRODUCTION
Autism spectrum disorder (ASD) is a complex spectrum of disorders
characterized by two typical abnormalities: (a) deficits of social commu-
nication and interaction; (b) the presence of restricted interests as well
as repetitive and stereotypic verbal and nonverbal behaviors.1,2 Com-
orbidities including sleep disorders, seizures, and gastrointestinal diffi-
culties are very common in children with ASD.3 The prevalence of
identified ASD is increasing.4 In 2016, the overall ASD prevalence
among children aged 4 years was 15.6 per 1000 (1/64),5 and the inci-
dence was 18.5 per 1000 (1/54) in 8-year-old children according to
Early Autism and Developmental Disabilities Monitoring Network
sites.6 The etiology of ASD is still not well understood. However, many
associated factors including genetic mutations, immune dysregulation,
hypoperfusion of some parts of the brain, exposure to maternal anti-
bodies during pregnancy, and weak functional connectivity across brain
regions are suggested to contribute to the development of ASD.7-11
Multiple approaches including behavioral therapy, occupational ther-
apy, speech therapy, and medications are required in the management of
ASD to ameliorate autistic symptoms. Educational and behavioral inter-
ventions have been recognized as crucial for the management of ASD in
children.12 The evidence indicates that young children with ASD benefit
from interventions that focus on improving social interaction, communi-
cation, and challenging behaviors.13,14 Unfortunately, many children who
receive those treatments remain significantly impaired.15
In search of better outcomes in the management of ASD, alterna-
tive and complementary treatments are being investigated. Recent
reports have suggested that stem cell transplantation result in
improvements in several different neurological conditions.16-18 The
suggested mechanisms of action of mesenchymal stem cells (MSCs)
on the nervous system include neuroprotection, neurogenesis, and
synaptogenesis.19-21
Stem cell applications were also assessed in animals using the
inbred BTBR T+tf/J (BTBR) mouse strain,22 which has autistic-like
symptoms, to explore the potential of stem cells in the management
of ASD. In BTBR mice, Segal-Gavish et al showed that transplantation
of MSCs resulted in a reduction in stereotypic behaviors, a decrease
in cognitive rigidity, and an improvement in social behavior. Moreover,
it has been shown that brain-derived neurotrophic factor protein
levels as well as neurogenesis increased in the hippocampus following
stem cell treatment.23 Similarly, Perets et al demonstrated that brain-
derived neurotrophic factors secreted by transplanted MSCs were a
key factor in the observed reductions in stereotypic behavior and in
the improvement of cognitive flexibility in the BTBR model.24 Ha et al
revealed that transplanted human adipose-derived stem cells
improved repetitive behaviors, social interaction, and anxiety in
valproic acid-induced ASD model mice.25
Based on results obtained from animal research, stem cell trans-
plantations have been conducted for children with ASD at several cen-
ters.26 Two distinct approaches have been explored thus far in the
application of cell therapy products for the treatment of ASD: culture
expanded and nonexpanded. In an early example of non-culture-
expanded cell therapy, Sharma et al described the use of autologous
bone marrow mononuclear cell (BMMNC) transplantation infused via
intrathecal route in 32 children with ASD. The procedure was reported
as being safe with minor adverse events encountered, such as nausea,
vomiting, and pain at the site of injection. Improvements were noticed
in different aspects, including social relationships and reciprocity,
speech and language patterns, and brain metabolism.27 A further exam-
ple of concentrated, but not expanded, cell therapy described the use
of autologous BMMNC transplantation via the intrathecal route in
10 children with ASD. The results revealed that the maximal treatment
effect was observed within the first 12 months with, again, with no
safety concerns.28 A combined culture-expanded/nonexpanded cell
therapy study reported on the outcomes of allogenic cord blood mono-
nuclear cell (CBMNC) transplantation vs CBMNC combined with umbil-
ical cord MSC transplantation for children with ASD.29 In this trial, four
stem cell infusions were carried out via intravenous and intrathecal
routes. No severe adverse events after cell transplantation were
Lessons learned
• The combination of cell therapy and educational interven-
tion may improve clinical manifestations such as social com-
munication, language, and daily skills in children with ASD.
Significance statement
The combination of cell therapy and educational interven-
tion may improve clinical manifestations, such as social com-
munication, language, and daily skills, in children with autism
spectrum disorder. However, additional studies with control
groups should be performed in the future to obtain a more
comprehensive and accurate conclusion.
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described for either group. Improved outcomes were noted in the com-
bination group compared with the CBMNC-alone group.
More recently, Dawson et al reported autologous stored cord blood
infusion through intravenous route in 25 children with ASD, which
resulted in significant improvements in behavior at 6 months after infu-
sion; these improvements were sustained at 12 months.30 That study
was followed by the first randomized, double-blind, placebo-controlled
clinical trial comparing outcomes of autologous cord blood infusion vs
placebo for children with ASD. As in all previous studies, autologous
intravenous cord blood infusion had no serious adverse events and
trended toward improvement, especially in socialization, but clinical out-
comes were not significantly different between the two groups.31
In summary, a number of clinical trials have been performed thus
far, exploring the application of cell therapy for the treatment of ASD.
Although the trials have been broadly consistent in outcome
reporting, disparities remain around cell sources, processing, dosage,
and delivery route. The aim of this study was to investigate the safety
and clinical outcomes of high-dosage BMMNC transplantation com-
bined with educational intervention for children with ASD.
2 | SUBJECTS, MATERIALS, AND
METHODS
2.1 | Patients
2.1.1 | Inclusion criteria
Patients of both sexes who were aged between 3 and 7 years with a con-
firmed diagnosis of ASD were enrolled. ASD was diagnosed according to
the diagnostic criteria for autism spectrum disorder in the Diagnostic and
Statistical Manual of Mental Disorders, Fifth Edition (DSM-5).1 All chil-
dren at Vinmec International Hospital who had severe ASD (Childhood
Autism Rating Scale [CARS] scores >37) were recruited for this study.
2.1.2 | Exclusion criteria
The exclusion criteria were epilepsy; hydrocephalus with ventricular
drain; coagulation disorders; allergy to anesthetic agents; severe
health conditions such as cancer or heart, lung, liver, or kidney failure;
and active infections. Patients with Rett syndrome or fragile X syn-
drome were also excluded from this study.
2.2 | Study design
This study was an open-label uncontrolled clinical trial of 30 patients
with ASD. The study commenced in July 2017 and was completed in
August 2019. The sponsor and investigators are responsible for the
publication of the trial results in accordance with the Consolidated
Standards of Reporting Trials (CONSORT)32 guidelines.
2.3 | Clinical assessment
Adverse events and serious adverse events were monitored and
assessed throughout the entire monitoring period of the study. Com-
plications were recorded during the process of bone marrow collec-
tions, stem cell infusions, and monitoring period of 48 hours
posttransplantation, 1-week postinjection by telephone, and then dur-
ing regularly visits.
Clinical examinations were performed at baseline and then at
6, 12, and 18 months after the first transplantation by an experienced
pediatric psychologist and a pediatric psychiatrist who were not mem-
bers of the research team. Multiple tools were used to diagnose and
determine the severity of ASD level, including DSM-5, CARS, the
Vineland Adaptive Behavior Scales Second Edition (VABS-II), and the
Clinical Global Impression (CGI). DSM-5, which was published in May
2013, provides new diagnostic criteria for ASD. The severity of ASD
is classified into three levels: level 1 (“Requiring support”), level
2 (“Requiring substantial support”), and level 3 (“Requiring very sub-
stantial support”).33
CARS consists of 14 domains assessing behaviors associated with
ASD, with a 15th domain rating general impressions of ASD.34 VABS-
II is a standardized measure35 that yields an overall score and subscale
standard scores in the four different domains: socialization, communi-
cation, daily living skills, and motor skills. CGI is a rating scale that
measures symptom severity and treatment response.36 The severity is
categorized into seven levels: (a) not present (no ASD), (b) barely evi-
dent ASD symptoms, (c) mild ASD symptoms, (d) moderate ASD
symptoms, (e) moderately severe ASD symptoms, (f) severe ASD
symptoms, or (g) very severe ASD symptoms. The response of each
patient is also divided into seven levels: level 1, very much improved;
level 2, much improved; level 3, minimally improved; level 4, no
change; level 5, minimally worse; level 6, much worse; and level 7, very
much worse. In addition, main indicators including social interaction,
eye contact, expressive language, abnormal behaviors, sensory abnor-
malities, eating and sleeping difficulties, daily skills, and learning
capacity before and after transplantation were collected to examine
the effects of stem cell therapy in combination with behavioral
intervention.
A brief video was recorded at baseline and then at 6, 12, and
18 months after the first transplantation. A questionnaire was com-
pleted by patients' caregivers 6 and 18 months after the first trans-
plantation to obtain their assessment and satisfaction. A
psychologist kept contact with patients' caregivers via telephone
throughout the follow-up period to record any unexpected events
during the study.
2.4 | Laboratory and imaging diagnostics
Routine hematologic and biochemistry examinations were performed
at baseline and 6 months later. Diagnostic imaging examinations,
including brain magnetic resonance imaging (MRI) and
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electroencephalography (EEG), were carried out in all patients at base-
line to rule out epilepsy and brain malformations.
Positron emission tomography-computed tomography (PET-CT)
was carried out before stem cell transplantation and retaken
12 months after the first transplantation to monitor changes of brain
metabolism. On post hoc analysis, decreased and increased
fluorodeoxyglucose (FDG) metabolism regions in autistic children
were evaluated based on a normal distribution curve. If the measured
value is lower than one SD from the median value of the standardized
uptake value, it is considered to be hypometabolic, whereas a mea-
sured value greater than a SD from the median value is considered to
be an increase in metabolism.37
In evaluation of PET-CT images, dark blue brain areas were
defined as severely reduced FDG metabolic rate, and light blue brain
areas were assessed as moderate metabolism. Green was considered
to have mild metabolic reduction. The yellow-orange brain region was
assessed to exhibit increased FDG metabolism.38
2.5 | Genetic screening, data analysis, and
validation
Microarray comparative genomic hybridization (CGH) and whole
exome sequencing tests were performed in 28 children (two families
declined genetic screening). The GenetiSure Cancer Research CGH
+SNP Microarray, 2x400K Kit (Agilent Technologies, Santa Clara, Cal-
ifornia) was used for CGH testing to detect copy number variations
(CNVs). This technique uses a “two-color” process to measure DNA
copy number changes in an experimental sample relative to a refer-
ence sample. An Agilent Microarray Scanner was used to scan the
slides and export the data through Agilent Feature Extraction soft-
ware. The first quality control filter of <0.23 derivative log-ratio
threshold was the cutoff. The ADM-2 algorithm in Cytogenomics
software was applied to all CNVs and filtered by the DGV, NSTD100,
ISCA, and SFARI databases to shortlist the candidate CNVs related to
ASD, and the CNVs were classified according to the American Col-
lege of Medical Genetics and Genomics 2016 guidelines. The candi-
date CNVs were validated by real-time polymerase chain reaction. A
Rapid Capture Exome Kit (Illumina, San Diego, California) was used
for library preparation. Paired-end exome sequencing with a read
length of 75 × 2 base pairs was performed on a HiSeq 4000
(Illumina). After sequencing, low-depth reads and adapters were
removed prior to downstream analysis. Burrows-Wheeler Aligner was
used for alignment using the human Genome Reference Consortium
Human Build 37 (GRCh37) reference genome.39 The Genome Analy-
sis Toolkit40 and SnpEff (an open-source tool that annotates variants
and predicts their effects on genes)41 were used for variant calling
and annotation, respectively. Candidate variants were validated by
Sanger sequencing on the ABI 3500 DX system. In silico tools, includ-
ing PolyPhen-2,42 Scale Invariant Feature Transform,43
MutationTaster,44 and SnpEff,41 were used to predict the impact of
missense variants. The effect of splice site variants was predicted by
Human Splicing Finder.45
2.6 | Bone marrow aspiration
For each transplantation, bone marrow was harvested through ante-
rior iliac crest puncture under general anesthesia in the operating the-
ater. The volume collected depended on the patients' body weight as
follows: 8 mL/kg for patients under 10 kg (80 mL + [body weight in
kg − 10] × 7 mL) for patients above 10 kg, based on our experience
from a previous study.17
2.7 | BMMNC isolation, characterization, and
preparation for transplantation
BMMNCs were isolated by gradient centrifugation using Ficoll-
Paque (GE Healthcare, Waukesha, Wisconsin) in our ISO 14644
standard clean room at Vinmec Research Institute of Stem Cell and
Gene Technology. The cell suspension was washed with 1×
phosphate-buffered saline solution and resuspended in autologous
plasma up to a total of 10 mL for injection. The sterility of the prod-
uct was confirmed by microbiological evaluation using the BacT/
Alert3D microbial detection system (bioMérieux, Durham, North Car-
olina). The total blood components before and after Ficoll-Paque
separation were evaluated with a Beckman Coulter LH780
hematocytometer. The hematopoietic stem cell CD34+ (hHSC
CD34+) count was assessed using Stem-Kit Reagent (Beckman Coul-
ter, Brea, California) on a Navios flow cytometer (Beckman Coulter).
Before injection, cell products were examined for endotoxin levels
using the Endosafe-PTS kit (Charles River Laboratories, Cambridge,
Massachusetts) and Mycoplasma using the MycoAlert Mycoplasma
Detection Kit (Lonza, Basel, Switzerland).
2.8 | BMMNC transplantation
Each patient underwent two BMMNC transplantations with an inter-
val of 6 months. The average mononuclear cell and CD34+ cell counts
per kg body weight were 42.3 × 106/kg and 2.6 × 106 for the first
transplantation and 40.9 × 106/kg and 2.1 × 106 for the second trans-
plantation, respectively. The average cell viabilities before the first
and second transplantations were 97.6% and 98.7%, respectively.
Each dose of cells was mixed with physiological saline to a volume of
5 mL for administration. Cells were then intrathecally infused into the
space between the fourth and fifth lumbar vertebrae using an
18-gauge needle. This procedure was conducted in the recovery room
by an experienced anesthesiologist and lasted 30 minutes.
2.9 | Post-BMMNC transplantation therapy
All patients underwent 8 weeks of educational intervention, 2 hours
per day, 5 days per week, at the day clinic of Vinmec International
Hospital. The educational intervention was developed based on the
Early Start Denver Model manual.15,46
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2.10 | Ethics statement
The study protocol was reviewed and approved by the Ethics
Committee of Vietnam Ministry of Health on 20 June 2017, with
number 72/CN-BDGDD. The study was registered on ClinicalTrials.
gov on 21 July 2017, with identity number NCT03225651.
The study protocol was reviewed and approved by the Institutional
Review Board of Vinmec International Hospital on 31 March 2017. The
reference number for the ethics committee is 310317/2017/QD-
VINMEC. The committee evaluated the ethical aspects of the study in
accordance with The World Medical Association's Declaration of Hel-
sinki. The study was explained in detail to the parents of the partici-
pants. Written informed consent was obtained from the parents well
before patient enrollment in all cases. Written informed consent was
obtained from the subjects' parents well before patient enrollment in all
cases. This consent included their agreement to the publication of indi-
rect patient identifiers, such as age and gender.
2.11 | Statistical analysis
Each individual is a unit of analysis. The Wilcoxon signed-rank test
was used to compare the total CARS scores and VABS scores at
6, 12, and 18 months with those at baseline. Mixed-effects analy-
sis was used to evaluate the changes in CARS scores. A value of
P < .05 was considered statistically significant. All statistical ana-
lyses were performed using R software version 3.4.4.
3 | RESULTS
3.1 | Patient characteristics
Thirty patients, including 25 boys and 5 girls with a mean age of
5.6 ± 0.9 years (range 3.0-7.4 years) and a mean weight of
19.9 ± 3.6 kg, were enrolled in this study. All patients underwent
educational intervention before the first transplantation with an
average duration of 34 ± 17.5 months. The age when those children
received such educational intervention was 26.4 ± 5.8 months at
different centers.
At baseline, all patients were categorized at a severe level with
CARS scores ranging from 40 to 55.5. According to the DSM-5 classi-
fication, 28 patients were classified as level 3, and 2 patients were
classified as level 2. CARS scores and VABS scores at baseline are
shown in Table 1.
Adaptive behavior skills were low in all patients, with VABS
scores ranging from 41 to 65. Before BMMNC transplantation, only
37% of the children could have social contact, and 23% made eye
contact; meanwhile, the rates of no eye contact and not showing
affection toward parents were 77% and 87%, respectively. Expressive
language occurred in 47% of children (Table 2).
Abnormal behaviors were observed in a high percentage of chil-
dren. Regarding stereotypic behaviors, 93% of the children displayed
repetitive behavior and 83% restricted interest. Hyperactivity was
noted in 28 patients (93%) (Table 3). Sensory abnormalities occurred
in 29 children (97%), picky eating in 21 children (70%), and sleeping
difficulties in 16 children (53%) (Table 4).
3.2 | Genetic testing
We detected and validated a de novo CNV in the SHANK3 gene from
a female proband (proband A27) and 23 different variants in 22 genes
from eight probands (Table 5). Among them, 15 variants were
recorded in dbSNP, most of which have not been reported to have
clinical significance. TRIOS analysis revealed the inheritance mode of
the variants where two probands (probands A11 and A13) carried
autosomal recessive variants, three probands carried X-linked variants
(A17, A22, and A29), and the rest carried de novo variants. In terms of
variant type, although most of them were missense, we observed
three loss-of-function variants (two frameshift and one deletion) in
three male probands (proband A6, A13, and A29). Our in silico ana-
lyses showed that almost all variants had a damaging impact on the
gene's function. We found that 41% of the total detected genes har-
boring variants were recorded in the ASD database, including ANK2,
CASK, CHD8, GALNT14, GIGYF2, GRIN2A, MUC4, NOS1, and XIRP1.
TABLE 1 Median Childhood Autism Rating Scale (CARS) and Vineland Adaptive Behavior Scale scores at baseline and after
transplantation (n = 30)
Category
Baseline,
median (range)
After 6 months,
median (range)
After 12 months,
median (range)
After 18 months,
median (range)
CARS score 50 (40-55.5) 49.5 (36-55)* 47.3 (35.5-53.5)* 46.5 (33.5-53.5)*
Vineland standard score 53.5 (40-65) 55.5 (42-66)* 58.5 (43-71)* 60.5 (44-76)*
Communication 47 (38-67) 47 (36-74) 51 (36-71)* 56 (36-79)*
Daily living skills 58 (38-75) 58 (36-79) 65.5 (40-85)* 67.6 (40-89)*
Socialization 55 (46-65) 53 (44-68) 59 (46-68)* 59 (50-74)*
Motor skills 64 (38-78) 64 (49-81) 64 (52-81) 67 (51-89)*
*P < .05 (Wilcoxon signed-rank test compared with baseline).
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TABLE 3 Abnormal behaviors before and after transplantation (n = 30)
Domain
Before transplantation,
n (%)
After 6 months,
n (%)
After 12 months,
n (%)
After 18 months,
n (%)
Stereotypic/repetitive behaviors
Have repetitive behavior 28 (93) 26 (87) 26 (87) 26 (87)
No repetitive behavior 2 (7) 4 (13) 4 (13.3) 4 (13)
Restricted interests
Have restricted interests 25 (83) 25 (83) 23 (77) 22 (73)
No restricted interests 5 (17) 5 (17) 7 (23) 8 (27)
Hyperactivity
Have hyperactivity 28 (93) 27 (90) 21 (70) 13 (43)
No hyperactivity 2 (7) 3 (10) 9 (30) 17 (57)
Self-injurious behavior
Have self-injurious behavior 6 (20) 6 (20) 5 (17) 2 (7)
No self-injurious behavior 24 (80) 24 (80) 25 (83) 28 (93)
TABLE 4 Sensory abnormalities, eating difficulties and sleep problems before and after transplantation (n = 30)
Domain
Before transplantation,
n (%)
After 6 months,
n (%)
After 12 months,
n (%)
After 18 months,
n (%)
Sensory impairments
Have sensory abnormalities 29 (97) 28 (93) 24 (80) 22 (73)
No sensory abnormalities 1 (3) 2 (7) 6 (20) 8 (27)
Picky eating behaviors
Have picky eating behavior 21 (70) 20 (67) 18 (60) 14 (47)
No picky eating behavior 9 (30) 10 (33) 12 (40) 16 (53)
Sleep problems
Have sleep problems 16 (53) 15 (50) 14 (47) 13 (43)
No sleep problems 14 (47) 15 (50) 16 (53) 17 (57)
TABLE 2 Social interaction, eye contact, and expressive language before and after transplantation (n = 30)
Domain
Before transplantation,
n (%)
After 6 months,
n (%)
After 12 months,
n (%)
After 18 months,
n (%)
Social interaction
No social interaction 19 (63) 12 (40) 7 (23) 1 (3)
Capable of social interaction 11 (37) 18 (60) 23 (77) 29 (97)
Eye contact
No eye contact 23 (77) 17 (57) 4 (13) 2 (7)
Occasional or normal eye contact 7 (23) 13 (43) 26 (87) 28 (93)
Expression of feelings to parents
Showing affection 26 (87) 26 (87) 29 (97) 29 (97)
Not showing affection 4 (13) 4 (13) 1 (3) 1 (3)
Expressive language
No language 16 (53) 10 (33) 4 (13) 2 (7)
Capable of expressive language 14 (47) 20 (67) 26 (87) 28 (93)
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SHANK3, CHD8, ANK2, and GIGYF2 belong to the genes with the
strongest evidence of relevance to ASD.
3.3 | Brain MRI and EEG
No abnormalities on MRI or EEG were observed in any of the
patients.
3.4 | FDG changes after BMMNC transplantation
At baseline, manifestation of hypometabolism was found at seven
major brain regions: hippocampus, anterior cingulate gyrus, posterior
cingulate gyrus, parietal lobe, frontal lobe, temporal lobe, and central
sulcus. After the stem cell transplant, 29 children underwent a second
PET-CT scan (the parent refused the second PET-CT in one patient).
Improvement in metabolism was observed in some brain regions
where severe hypometabolism was noticed before BMMNC trans-
plantation such as parietal lobe, frontal lobe, and anterior cingulate
gyrus. However, these changes were not statistically significant
(Table 6).
3.5 | Adverse events
None of the patients had any severe adverse events during bone mar-
row aspiration, stem cell infusion, or following transplantation. The
procedure was reported as being safe with minor adverse events
encountered. There were no procedure-related major adverse events.
Among 96 adverse events that occurred during study period,
46 (48%) mild and moderate adverse events were recorded that may
or may not be related to BMMNC transplantation with symptoms
including pain, vomiting, and mild fever. All those adverse events were
easily managed through appropriate medication (Table 7).
3.6 | Clinical outcomes
After BMMNC transplantation, the severity of ASD decreased
remarkably. The median CARS scores decreased from 50 (range
40-55.5) points at baseline to 46.5 (range 33.5-53.5) after 18 months.
Patient-specific CARS score analysis for each patient is presented in
Figure 1. The result of the mixed-effects analysis suggests that each
visit was associated with a decrease of 1.6 in the CARS score and that
this change was statistically significant (Table 8).
TABLE 6 Brain metabolism of autistic children before and after stem cell transplantation as assessed by positron emission tomography-
computed tomography examination (n = 29)
Regions
Severe hypometabolism, % Moderate hypometabolism, % Light hypometabolism, % No change, %
Before
(n = 29)
After
(n = 29)
Before
(n = 29)
After
(n = 29)
Before
(n = 29)
After
(n = 29)
Before
(n = 29)
After
(n = 29)
Hippocampus 3.4 0 41.4 27.6 17.2 66 38 6.4
Anterior cingulate gyrus 31 13.8 48.3 51.7 10.3 10.3 10.3 24.2
Posterior cingulate gyrus 6.9 3.4 10.3 3.4 6.7 0 76.1 93.2
Parietal lobe 24.1 0 31 13.8 10.3 31 34.6 55.2
Frontal lobe 24.1 3.4 24.1 0 3.4 31 48.4 65.6
Temporal lobe 6.9 0 37.9 10.3 10.3 20.7 44.9 69
Central sulcus 0 0 3.4 10.3 3.4 27.6 93.2 62.1
TABLE 7 Summary of the number of adverse events (AEs) and serious adverse events (SAEs) occurring during the study
AE/SAE n (%)
Classification
of AE/SAE Note
Serious adverse events 0 SAE
AE was not associated with
the intervention
26 (27.1) AE Nonallergic rhinitis, tonsillitis, cold urticaria, leg pain, poor
appetite, abrasions
AE was less associated with
the intervention
27 (28.1) AE Skin rash, pale skin, pale mucous membranes, fussing, lack of
sleep, fatigue
AE may be related to the
intervention
17 (17.7) AE Mild fever, nausea, vomiting
AE related to the intervention 26 (27.1) AE Pain, broken vein, peripheral vein masonry, slipping needle
out of the vein during transplantation
Total 96
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According to the DSM-5 classification, the number of patients at
level 3 was reduced from 28 to 18. There were no patients at level
1 before transplantation, but after transplantation, five children were
recategorized at this level.
After transplantation, improvements were observed in various
aspects. Social interaction and eye contact increased remarkably from
37% before the first transplantation to 97% and from 23% to 93%,
respectively, after 18 months. Expressive language increased from
47% before transplantation to 67% after 6 months, 87% after
12 months, and 93% after 18 months (Table 2). Abnormal behaviors
also decreased after transplantation. The children with repetitive
behavior decreased from 93% to 87% (Table 3). Sensory abnormalities
and sleeping difficulties progressively improved after transplantation,
from 97% to 73% and from 53% to 43%, respectively (Table 4).
Improvements of adaptive behavior scales after transplantation are
noted in VABS scores, including communication, daily living skills, and
socialization. Specifically, the Vineland standardized scores increased
significantly from 52.4 ± 7 to 60.4 ± 7.4. This increase in adaptive
ability was found in all four different domains: from 49 ± 8.3 to
56.1 ± 9.8 in communication, from 55.7 ± 10.1 to 67.1 ± 12 in daily
living skills, from 54.5 ± 5.4 to 58.9 ± 5.5 in socialization, and from
60.1 ± 14.7 to 67.8 ± 8.6 in motor skills (Table 1).
According to teachers' evaluations, 28 children exhibited
improvements compared with baseline, including 5 patients who
improved very much, 17 who improved much, and 6 who improved
minimally. Two children exhibited very minimal changes when com-
pared with the baseline assessment. In addition, parents' satisfaction
with the intervention increased from 93% at 6 months to 97% at
18 months of BMMNC treatment.
4 | DISCUSSION
In this study, bone marrow was collected from anterior iliac crests and
not from posterior crests as in other reports.17,27 This change facili-
tated anesthesia and reduced risks related to the prone position of
patients. The dosage of transplanted mononuclear cells and CD34+
cells in our study was higher than those in studies reported by
Sharma, Dawson, and Chez.27,30,31 Differences related to the cell
transplants compared with other studies are presented in Table 9.
Granulocyte-colony stimulating factor (G-CSF) was not used in this
study to mobilize stem cells from bone marrow, with high dosage
values nevertheless isolated. This implies that G-CSF may not be
F IGURE 1 Childhood autism rating scale
(CARS) scores for 30 children with autism
spectrum disorder (ASD) before and after stem
cell transplantations (SCTs)
TABLE 8 The results from the mixed-effects analysis of
Childhood Autism Rating Scale scores
Fixed effects Estimate ± SE t value
(Intercept) 51.60000 ± 0.91245 56.55
Visit −1.62167 ± 0.09957 −16.29
Correlation of fixed effects
(Intr)
Visit −0.273
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necessary for the collection of BMMNCs in children. Our results dem-
onstrated that high-dosage transplantation of autologous bone mar-
row stem cells was well tolerated. There were no observed severe
adverse events in any patients during or following transplantation.
The incidence of minor adverse events was low and easily managed
through medication or spontaneously resolved themselves.
Although all participants still belonged to severe level at the base-
line after receiving behavioral intervention with a mean duration of
3.5 years, this study showed improvements in various aspects after
BMMNC transplantation combined with educational intervention.
Positive changes in social communication, eye contact, language,
behaviors, and daily skills were observed after BMMNC transplanta-
tion. In addition, learning ability also remarkably improved after trans-
plantation. The number of children who could go to school without
support increased after transplantation (Table 10).
Hyperactivity of children with ASD is a disorder that severely
impairs quality of life for the whole family. In our study, the rate of
children with hyperactive disorder decreased by 50% at 18 months
after stem cell transplantation.
Positive changes were found in evaluation measures, including
severity and adaptive ability. The number of patients at level
3 (requiring very substantial support) according to DSM-5 decreased
from 28 to 18 at 18 months after transplantation.
We noticed that the improvements appeared to be influenced by
the CARS scores at baseline. Patients with a CARS score ≤49 at base-
line showed better improvement than those who had CARS scores
>49 points. This would imply that patients with lesser severity had
better outcomes after transplantation.
Genetic abnormalities have been reported in many ASD studies.
In our series, genetic variations were found in eight patients (26%).
Among the detected genes, CHD8, ANK2, and SHANK3 have been
well identified as ASD risk genes.48,49 Meanwhile, some genes have
been found to associate with neurodevelopmental disorders (CASK
and CHD8)50 or to be involved in synapse transmission, such as IGF1
(proband A3),51 PIGG (proband A27),52 SYP,53 and LAS1 L.54 Among
those eight children, clinical improvements were observed in seven
patients at different levels after BMMNC transplantation, whereas
one patient (proband A27), who carried multiple genetic abnormalities,
exhibited the least progress.
Stem cell transplantations display effects in some studies linked
to ASD; however, there are still ongoing controversial discussions
concerning the most appropriate stem cell source, preparation, stem
TABLE 9 Number of cells by study
Author Cell type Number of cells Number of CD34+ cells Route
Chez et al31 Autologous umbilical cord
blood mononuclear cell
16.16 × 107 cells/kg 0.29 × 105 cells/kg Peripheral i.v.
Dawson et al30 Autologous umbilical cord
blood mononuclear cell
2.6 × 107 cells/kg 0.3 × 105 cells/kg Intravenous
Sharma et al27 Autologous BMMNC 8.9 × 107 cells — Intrathecal
Liem et al47 Autologous BMMNC First dose: 42.3 × 106 MNCs/kg
Second dose: 40.9 × 106 MNCs/kg
First dose: 2.6 × 106 cells/kg
Second dose: 2.1 × 106 cells/kg
Intrathecal
Abbreviations: BMMNC, bone marrow mononuclear cell; MNC, mononuclear cell.
TABLE 10 Daily skills and learning capacity before and after transplantation (n = 30)
Domain
Before transplantation,
n (%)
After 6 months,
n (%)
After 12 months,
n (%)
After 18 months,
n (%)
Self-feeding
Unable to self-feed 13 (43) 4 (14) 1 (3) 1 (3)
Need support to self-feed 13 (43) 16 (53) 11 (37) 10 (33)
Able to self-feed 4 (14) 10 (33) 18 (60) 19 (64)
Toileting skills
Unable to go to toilet 17 (56) 12 (40) 7 (23) 6 (20)
Need support to go to toilet 11 (37) 14 (47) 11 (37) 10 (33)
Able to go to toilet 2 (7) 4 (13) 12 (40) 14 (47)
Learning ability
Unable to integrate into school 16 (53) 15 (50) 11 (37) 8 (27)
Need support to integrate into school
(with help from teachers)
14 (47) 15 (50) 18 (60) 19 (63)
Go to school normally 0 0 1 (3) 3 (10)
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cell dosage, delivery routes, and study follow-up schedules after trans-
plantation. Different sources of stem cells have been explored as
potential cell therapies for ASD, including umbilical CBMNCs, umbili-
cal cord tissue MSCs, and BMMNCs.27-31
The safety and efficacy of autologous BMMNC transplantation
has been shown for many neurologic conditions.27,28,47,55,56 We pro-
pose that autologous BMMNCs are a suitable cell source for applica-
tion in the management of ASD.
Two different pathways for administration have been applied
in the delivery of cell therapy for ASD: intravenous and intrathecal.
Although both delivery routes are safe, there are concerns regard-
ing cells delivered through the intravenous route, as transplanta-
tions in animal models have shown that the transplanted cells have
difficulties passing through organs such as the spleen, kidney, and
intestine.57 The intrathecal route does not present this concern.
The number of BMMNCs transplanted also varies between studies,
and the number we have used was higher than those from other
groups.27-31 There have been suggestions of correlation between
transplanted stem cell dosage and the extent of subsequent clinical
improvement.58 Although we did not perform an escalating dosage
study, we noted that a high dosage of stem cells may be used to
obtain satisfactory outcomes in children with ASD. Furthermore,
we performed two transplantations instead of one transplantation
as described elsewhere.27,30,31 Multiple transplantations have
resulted in positive outcomes in both ASD29 and spinal cord
injury.59 Moreover, the benefits of repeated transplantations vs sin-
gle transplantation have been identified in animal myocardium
infarction models.60
In our study, all children received 18 months of follow-up after
the first transplantation. This follow-up duration exceeds those in
other recent reports.27,29-31 We noticed that the longer the
follow-up duration was, the lower the severity of ASD (CARS
score reduction) and the better the children's adaptive functioning
(VABS score increase). Meanwhile, there was no case in which the
results were not improved or even worse compared with baseline,
implying that the treatments have a sustainable long-term effect. It
is likely that further extended follow-up times will be required to
fully assess the responses of children with ASD over time after
stem cell transplantation. Herein, we have demonstrated the safety
and feasibility of BMMNC transplantation for the treatment of
ASD. The lack of a control group who received either stem cell
transplantation or educational intervention only is a limitation of
this study. However, our study results provide initial evidence to
justify conducting a randomized clinical trial with control groups in
the future.
5 | CONCLUSION
We conclude that autologous BMMNC transplantation is safe. The
combination of cell therapy and educational intervention may improve
clinical manifestations such as social communication, language, and
daily skills in children with ASD. However, additional studies with
control groups should be performed in the future to obtain a more
comprehensive and accurate conclusion.
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